Seenu Hariprasad to Ranibizumab
This is a "connection" page, showing publications Seenu Hariprasad has written about Ranibizumab.
Connection Strength
0.940
-
Long-term effect of anti-vascular endothelial growth factor injections on intraocular pressure. Indian J Ophthalmol. 2016 Sep; 64(9):643-647.
Score: 0.146
-
DRCR Protocol-T: Reconciling 1- and 2-Year Data for Managing Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2016 Apr 01; 47(4):308-12.
Score: 0.141
-
Effect of Fluid Status at Week 12 on Visual and Anatomic Outcomes at Week 52 in the VIEW 1 and 2 Trials. Ophthalmic Surg Lasers Imaging Retina. 2016 Mar; 47(3):238-44.
Score: 0.141
-
Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T. Ophthalmic Surg Lasers Imaging Retina. 2015 Mar; 46(3):302-5.
Score: 0.131
-
The evolving paradigm for the treatment of diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina. 2013 Jul-Aug; 44(4):324-8.
Score: 0.117
-
Current concepts in managing wet AMD suboptimally responsive to anti-VEGF therapy. Ophthalmic Surg Lasers Imaging Retina. 2013 May-Jun; 44(3):225-6.
Score: 0.115
-
Review of ranibizumab trials for neovascular age-related macular degeneration. Semin Ophthalmol. 2011 Nov; 26(6):372-9.
Score: 0.104
-
Bacterial contamination of needles used for intravitreal injections: a prospective, multicenter study. Ocul Immunol Inflamm. 2011 Feb; 19(1):32-8.
Score: 0.024
-
Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration. Br J Ophthalmol. 2008 Apr; 92(4):584.
Score: 0.020